NPS Pharmaceuticals 8-K 2014
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
June 10, 2014
Date of Report (Date of earliest event reported)
NPS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
550 Hills Drive, 3rd Floor
Bedminster, NJ 07921
(Address of principal executive offices)
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On June 10, 2014, NPS Pharmaceuticals, Inc. (NPS), reported that the U.S. Food and Drug Administration (FDA) shifted the tentative date for the Natpara® (rhPTH[1-84]) Advisory Committee Meeting from July 24 to September 12, 2014. A definitive date for the advisory committee meeting is expected to be published by FDA in the Federal Register at least 15 days prior to such meeting. The Prescription Drug User Fee Act (PDUFA) Action Date of October 24, 2014 remains unchanged.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.